[1]BioorganicandMedicinalChemistryLetters,2003,vol.13,p.1857-1859
[1]Tetrahedron,2003,vol.59,p.7215-7229
[2]Patent:WO2004/6928,2004,A1.Locationinpatent:Page/Pagecolumn13
[1]Tetrahedron,2003,vol.59,p.7215-7229
[2]BioorganicandMedicinalChemistryLetters,2011,vol.21,p.1649-1653
[1]Tetrahedron,2003,vol.59,p.7215-7229
[1]Tetrahedron,2003,vol.59,p.7215-7229
[2]Tetrahedron,2003,vol.59,p.7215-7229
[3]BioorganicandMedicinalChemistryLetters,2011,vol.21,p.1649-1653
Title: Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.
Journal: Scientific reports 20140101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: PROX1 overexpression inhibits protein kinase C beta II transcription through promoter DNA methylation.
Journal: Genes, chromosomes & cancer 20121101
Title: NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.
Journal: Expert opinion on investigational drugs 20121101
Title: Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.
Journal: American journal of clinical oncology 20121001
Title: Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Journal: Annals of hematology 20121001
Title: A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands) 20121001
Title: A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands) 20121001
Title: A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120915
Title: A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
Journal: Cancer 20120901
Title: Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.
Journal: Leukemia & lymphoma 20120501
Title: Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro.
Journal: Endocrinology 20120501
Title: Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Journal: Expert opinion on investigational drugs 20120501
Title: Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
Journal: Investigational new drugs 20120401
Title: A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology 20120401
Title: A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
Journal: Neuro-oncology 20120301
Title: Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.
Journal: British journal of cancer 20120227
Title: Novel targeted therapies for mantle cell lymphoma.
Journal: Oncotarget 20120201
Title: miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
Journal: PloS one 20120101
Title: The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Journal: PloS one 20120101
Title: A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
Journal: Oncology 20120101
Title: 14-3-3ζ interacts with stat3 and regulates its constitutive activation in multiple myeloma cells.
Journal: PloS one 20120101
Title: Novel therapies for aggressive B-cell lymphoma.
Journal: Advances in hematology 20120101
Title: Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Journal: PloS one 20120101
Title: The first European interdisciplinary ewing sarcoma research summit.
Journal: Frontiers in oncology 20120101
Title: Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.
Journal: Investigational new drugs 20111201
Title: Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
Journal: Head & neck 20111201
Title: Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Journal: Neuro-oncology 20111201
Title: Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Journal: British journal of cancer 20111108
Title: Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice.
Journal: Free radical biology & medicine 20111101
Title: Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
Journal: Current cancer drug targets 20111101
Title: Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Journal: Current cancer drug targets 20111101
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110901
Title: Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review.
Journal: Journal of neuro-oncology 20110901
Title: HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
Journal: Apoptosis : an international journal on programmed cell death 20110901
Title: Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma.
Journal: Head & neck 20110801
Title: Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
Journal: Endocrine-related cancer 20110801
Title: Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.
Journal: Expert opinion on investigational drugs 20110801
Title: Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.
Journal: Leukemia & lymphoma 20110801
Title: Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Journal: Expert opinion on investigational drugs 20110801
Title: Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin.
Journal: The Journal of investigative dermatology 20110701
Title: A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Journal: American journal of hematology 20110701
Title: Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.
Journal: Journal of cellular biochemistry 20110601
Title: A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Journal: Gynecologic oncology 20110601
Title: Pathway inhibition: emerging molecular targets for treating glioblastoma.
Journal: Neuro-oncology 20110601
Title: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Journal: Journal of neuro-oncology 20110501
Title: Impact of metal-induced degradation on the determination of pharmaceutical compound purity and a strategy for mitigation.
Journal: Journal of pharmaceutical and biomedical analysis 20110405
Title: Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis.
Journal: Journal of hepatology 20110401
Title: [11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C.
Journal: Bioorganic & medicinal chemistry letters 20110315
Title: APC +/- alters colonic fibroblast proteome in FAP.
Journal: Oncotarget 20110301
Title: Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Journal: Investigational new drugs 20110201
Title: The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Journal: Anticancer research 20110201
Title: p73 as a pharmaceutical target for cancer therapy.
Journal: Current pharmaceutical design 20110201
Title: The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β.
Journal: Biochemical pharmacology 20110115
Title: Growth Inhibition and Induction of Apoptosis in SHG-44 Glioma Cells by Chinese Medicine Formula 'Pingliu Keli'.
Journal: Evidence-based complementary and alternative medicine : eCAM 20110101
Title: Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Journal: Neuro-oncology 20110101
Title: Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.
Journal: Korean journal of urology 20110101
Title: Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
Journal: Journal of carcinogenesis 20110101
Title: Changes in gene expression and cellular architecture in an ovarian cancer progression model.
Journal: PloS one 20110101
Title: Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities.
Journal: Journal of oncology 20110101
Title: Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study.
Journal: Radiation oncology (London, England) 20110101
Title: Cambogin is preferentially cytotoxic to cells expressing PDGFR.
Journal: PloS one 20110101
Title: Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells.
Journal: BMC cancer 20110101
Title: Picomolar dichotomous activity of gnidimacrin against HIV-1.
Journal: PloS one 20110101
Title: Targeted treatment for chronic lymphocytic leukemia.
Journal: OncoTargets and therapy 20110101
Title: Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.
Journal: Molecular cancer therapeutics 20101201
Title: [Chemotherapy and targeted treatments in glioblastomas].
Journal: Neuro-Chirurgie 20101201
Title: Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101201
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Journal: Breast cancer research and treatment 20101101
Title: Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Journal: Current oncology reports 20101101
Title: Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101101
Title: Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors.
Journal: Cancer science 20101001
Title: Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
Journal: Molecular cancer therapeutics 20101001
Title: Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules.
Journal: British journal of cancer 20100907
Title: Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
Journal: International journal of radiation oncology, biology, physics 20100801
Title: The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.
Journal: Gynecologic oncology 20100701
Title: A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701
Title: Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Journal: Neuro-oncology 20100601
Title: A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20100501
Title: Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20100501
Title: Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20100501
Title: Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
Journal: Molecular cancer therapeutics 20100501
Title: Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
Journal: Clinical lung cancer 20100501
Title: Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.
Journal: Leukemia & lymphoma 20100401
Title: Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100301
Title: Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301
Title: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301
Title: Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
Journal: Talanta 20100215
Title: A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
Journal: Neuro-oncology 20100201
Title: Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.
Journal: The Journal of biological chemistry 20100108
Title: Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
Journal: Current drug targets 20100101
Title: Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70.
Journal: Leukemia 20100101
Title: Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis.
Journal: American journal of physiology. Gastrointestinal and liver physiology 20100101
Title: Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signalling in malignant glioma cells.
Journal: European journal of cancer (Oxford, England : 1990) 20100101
Title: Protein kinase Calpha: disease regulator and therapeutic target.
Journal: Trends in pharmacological sciences 20100101
Title: MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.
Journal: BMC cancer 20100101
Title: Molecular profiling of endometrial malignancies.
Journal: Obstetrics and gynecology international 20100101
Title: Progress on antiangiogenic therapy for patients with malignant glioma.
Journal: Journal of oncology 20100101
Title: Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.
Journal: Journal of oncology 20100101
Title: LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Journal: BMC cancer 20100101
Title: Cellular responses to Cisplatin-induced DNA damage.
Journal: Journal of nucleic acids 20100101
Title: Signal transduction inhibitor therapy for lymphoma.
Journal: Hematology. American Society of Hematology. Education Program 20100101
Title: A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
Journal: Investigational new drugs 20091201
Title: Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20091201
Title: Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Journal: Anticancer research 20091201
Title: Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20090901
Title: Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation.
Journal: Translational oncology 20090818
Title: Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Journal: Cancer chemotherapy and pharmacology 20090801
Title: Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology.
Journal: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20090701
Title: Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
Journal: Molecular cancer therapeutics 20090701
Title: Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.
Journal: Cancer research 20090615
Title: Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer.
Journal: International journal of colorectal disease 20090601
Title: Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths.
Journal: Journal of medicinal chemistry 20090528
Title: Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Journal: Cancer letters 20090518
Title: A phase I trial of enzastaurin in patients with recurrent gliomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090515
Title: [Role of PKCbeta in the malignant tumors and enzastaurin, a PKCbeta inhibitor].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20090501
Title: Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents.
Journal: Mini reviews in medicinal chemistry 20090401
Title: PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Journal: Blood 20090319
Title: Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
Journal: Hematological oncology 20090301
Title: Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.
Journal: Cancer research 20090215
Title: Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
Journal: Blood 20090212
Title: Antiangiogenic drugs in ovarian cancer.
Journal: British journal of cancer 20090113
Title: In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Journal: Toxicologic pathology 20090101
Title: Role of PKCbeta in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target.
Journal: Clinical & experimental metastasis 20090101
Title: Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.
Journal: Head & neck oncology 20090101
Title: Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
Journal: Journal of biopharmaceutical statistics 20090101
Title: In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography.
Journal: Journal of oncology 20090101
Title: Current available therapies and future directions in the treatment of malignant gliomas.
Journal: Biologics : targets & therapy 20090101
Title: MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.
Journal: Journal of carcinogenesis 20090101
Title: Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.
Journal: British journal of cancer 20081202
Title: Exploring multi-targeting strategies for the treatment of gliomas.
Journal: Current opinion in investigational drugs (London, England : 2000) 20081201
Title: Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.
Journal: Translational oncology 20081201
Title: Waldenstrom macroglobulinemia.
Journal: Cancer letters 20081018
Title: Protein kinase C beta in malignant pleural mesothelioma.
Journal: Anti-cancer drugs 20081001
Title: [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001
Title: The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells.
Journal: Cancer letters 20080908
Title: Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Journal: British journal of cancer 20080902
Title: Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL.
Journal: Journal of neurochemistry 20080901
Title: Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
Journal: Biologics : targets & therapy 20080901
Title: Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.
Journal: British journal of cancer 20080805
Title: The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Journal: Leukemia & lymphoma 20080701
Title: Current aspects of targeted therapy in head and neck tumors.
Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 20080701
Title: Targeted treatment and new agents in diffuse large B-cell lymphoma.
Journal: Seminars in hematology 20080701
Title: Circulating endothelial cells in oncology: pitfalls and promises.
Journal: British journal of cancer 20080603
Title: Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.
Journal: Investigational new drugs 20080601
Title: Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C.
Journal: European journal of cancer (Oxford, England : 1990) 20080601
Title: Enzastaurin.
Journal: Expert opinion on investigational drugs 20080601
Title: Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
Journal: Molecular cancer therapeutics 20080601
Title: Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Journal: Cancer research 20080315
Title: Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion.
Journal: Cancer science 20080301
Title: Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301
Title: Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
Journal: Investigational new drugs 20080201
Title: A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20080201
Title: Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.
Journal: European journal of haematology 20080101
Title: A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Journal: Anti-cancer drugs 20080101
Title: Protein kinase C isozymes as therapeutic targets for treatment of human cancers.
Journal: Advances in enzyme regulation 20080101
Title: Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Journal: The oncologist 20080101
Title: Reduction of HLA-DR+ lymphocytes after treatment with enzastaurin in patients with metastatic thyroid cancer.
Journal: Chemotherapy 20080101
Title: [Protein kinases C: a new cytoplasmic target].
Journal: Bulletin du cancer 20080101
Title: Novel therapies in breast cancer: what is new from ASCO 2008.
Journal: Journal of hematology & oncology 20080101
Title: A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.
Journal: Clinical medicine. Oncology 20080101
Title: Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20071115
Title: Enzastaurin.
Journal: Current opinion in oncology 20071101
Title: Chemoradiotherapy in malignant glioma: standard of care and future directions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070910
Title: Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.
Journal: Journal of clinical pharmacology 20070901
Title: Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature.
Journal: Current oncology reports 20070901
Title: Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070801
Title: Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070801
Title: Survival improvement in thoracic cancer: progress from the last decade and beyond.
Journal: Lung cancer (Amsterdam, Netherlands) 20070801
Title: Lessons learned in the development of targeted therapy for malignant gliomas.
Journal: Molecular cancer therapeutics 20070701
Title: Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Journal: Blood 20070601
Title: Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments.
Journal: Investigational new drugs 20070601
Title: Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501
Title: Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Journal: Blood 20070215
Title: Synergistic antiglioma activity of radiotherapy and enzastaurin.
Journal: Annals of neurology 20070201
Title: Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Journal: Current treatment options in oncology 20070201
Title: Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas.
Journal: Biology direct 20070101
Title: Inorganic pyrophosphate generation by transforming growth factor-beta-1 is mainly dependent on ANK induction by Ras/Raf-1/extracellular signal-regulated kinase pathways in chondrocytes.
Journal: Arthritis research & therapy 20070101
Title: What is the right dose? The elusive optimal biologic dose in phase I clinical trials.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901
Title: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901
Title: The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
Journal: The Journal of investigative dermatology 20060701
Title: Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Journal: Molecular cancer therapeutics 20060701
Title: Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060601
Title: American Association for Cancer Research--97th annual meeting.
Journal: IDrugs : the investigational drugs journal 20060601
Title: Perspectives in central nervous system malignancies.
Journal: IDrugs : the investigational drugs journal 20060601
Title: Protein kinase C-beta as a therapeutic target in breast cancer.
Journal: Seminars in oncology 20060601
Title: Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.
Journal: International journal of clinical pharmacology and therapeutics 20051201
Title: The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Journal: Cancer research 20050815
Title: The evolution of cancer research and drug discovery at Lilly Research Laboratories.
Journal: Advances in enzyme regulation 20050101
Title: Hypoxia, tumor endothelium, and targets for therapy.
Journal: Advances in experimental medicine and biology 20050101
Title: Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
Journal: Bioorganic & medicinal chemistry letters 20030602
Title: Antiangiogenic effects of a protein kinase Cbeta-selective small molecule.
Journal: Cancer chemotherapy and pharmacology 20020101
Title: Graff JR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res, 2005, 65(16),
Title: Rovedo MA, et al. Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin. J Invest Dermatol, 2011, 131(7), 1442-1449.
Title: Podar K, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood, 2007, 109(4), 1669-1677.
